Description
Chinook Therapeutics is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing medicines for kidney diseases.
Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company’s second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors.
Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. It is conducting a Phase I/II clinical trial of BION-1301.
